| 2933.91.00 | 00 | Alprazolam (INN), camazepam (INN), chlordiazepoxide (INN), clonazepam (INN), clorazepate, delorazepam (INN), diazepam (INN), estazolam (INN), ethyl loflazepate (INN), fludiazepam (INN), flunitrazepam (INN), flurazepam (INN), halazepam (INN), lorazepam (INN), lormetazepam (INN), mazindol (INN), medazepam (INN), midazolam (INN), nimetazepam (INN), nitrazepam (INN), nordazepam (INN), oxazepam (INN), pinazepam (INN), prazepam (INN), pyrovalerone (INN), temazepam (INN), tetrazepam (INN) and triazolam (INN); salts thereof | kg | Free | | 15.4￠/kg + 149.5% |
| 2933.99.02 | 00 | 2-[4-[(6-Chloro-2-quinoxalinyl)oxy]phenoxy]- propionic acid, ethyl ester; and O,O-Dimethyl-S-[(4-oxo-1,2,3-benzotri- azin-3-(4H)-yl)methyl]phosphorodithioate | kg | Free | | 15.4￠/kg + 64.5% |
| 2933.99.06 | 00 | α-Butyl- α-(4-chlorophenyl)-1H-1,2,4- triazole-1- propanenitrile (Myclobutanil); and α-[2-(4-Chlorophenyl)ethyl]- α-phenyl-1H- 1,2,4-triazole-1-propanenitrile (Fenbuconazole) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 64.5% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4￠/kg + 52% |
| 2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2933.99.14 | 00 | 5-Amino-4-chloro- α-phenyl-3- pyridazinone | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 40.5% |
| 2933.99.55 | | Analgesics, antipyretics and nonhormonal anti-inflammatory agents | | 6.5% | Free (A*,AU,BH, CA,CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4￠/kg + 47.5% |
| 2933.99.65 | 00 | Anticonvulsants, hypnotics and sedatives | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 48.5% |
| 2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.10.70 | 00 | 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one; Ethyl 2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetate; Ethyl 2-(2-aminothiazol-4-yl)-2- methoxyiminoacetate; 2-Methyl-4-isothiazolin- 3-one; 2-n-Octyl-4-isothiazolin-3-one; and Thiothiamine hydrochloride | kg | Free | | 30.5% |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.20.25 | 00 | 2-Amino-5,6-dichlorobenzothiazole; 2-(4-Aminophenyl)-6-methylbenzothiazole-7- sulfonic acid; 2-Amino-6-nitrobenzothiazole; and N,N-Dicyclohexyl-2-benzothiazolesulfenamide | kg | Free | | 15.4￠/kg + 52% |
| 2934.20.30 | 00 | 2-Amino-6-methoxybenzothiazole; 2-Amino-6-methylbenzothiazole; 6-Ethoxy-2-benzothiazolethiol; 3-Methylbenzothiazole-2-hydrazone; and Primuline base | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4￠/kg + 52% |
| 2934.99.05 | 00 | 5-Amino-3-phenyl-1,2,4-thiadiazole (3-Phenyl-5-amino-1,2,4-thiadiazole); 2-Hydroxybenzoxazole (Benzoxazolone); 4-Phenylmorpholine; 1,9-Thianthrenedicarboxylic acid; and Thioxanthene-9-one (Thioxanthone) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.99.06 | 00 | 7-Nitronaphth[1,2]oxadiazole-5-sulfonic acid and its salts | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4￠/kg + 66.5% |
| 2934.99.09 | 00 | 1,2-Benzisothiazolin-3-one | kg | Free | | 15.4￠/kg + 40.5% |
| 2934.99.11 | 00 | 2-tert-Butyl-4-(2,4-dichloro-5- isopropoxyphenyl)- 2-1,3,4- oxadiazolin-5-one; 3-Isopropyl-1H-2,1,3- benzothiadiazin-4-(3H)-one-2,2- dioxide (Bentazon); and O,O-Diethyl-S-[(6-chloro-2- oxobenzoxazolin-3-yl)methyl]￠/phosphorodithioate (Phosalone) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 40.5% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2935.00 | | Sulfonamides: | | | | |
